Ann: Notification of cessation of securities - AVR, page-4

And to follow up with the options and warrants (they are almost all options), they are worth around $34 million if all are exercised not counting another 500,000 that are listed just as having various prices. At a low average price of $7, those 500,000 would bring in another $3.5 million. The expiration dates on those are from Jan 2024 to June 2027. Plus we will sell DurAVR's for trials according to Wayne, which will likely bring in another $5 million to $25 million depending on the number of patients enrolled in trials. So we are looking good financially going forward with the caveat as always being the best laid plans....